Erytech Pharma Inc.

123 articles with Erytech Pharma Inc.

• ERYTECH Expands Use of Medidata Cloud to Centrally Manage All Data for Oncology Trials

  11/7/2018

  French biopharmaceutical company aims to improve data access, quality, and workflow efficiencies

• ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018

  6/15/2018

  ERYTECH Pharma announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) at the European Hematology Association (EHA) Congress

• LYONBIOPOLE Will Unite Leading French Biotech Actors at the 2018 BIO International Convention

  5/31/2018

  Lyonbiopole the French "bio-cluster" based in the Auvergne-Rhône-Alpes region, will unite 35 innovative organizations at the 2018 edition of the BIO International Convention.

• ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase

  2/13/2018

  Following these very encouraging results, ERYTECH conducted a comprehensive evaluation to determine other potential solid-tumor indications for developing eryaspase.

• 

  ERYTECH's Lead AML Drug Flunks Phase II Test

  12/8/2017

  The study enrolled a total of 123 patients at 30 European sites.

• French Biotech ERYTECH Enters the Nasdaq and Raises $144M

  11/15/2017

  Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about November 16, 2017.

• ERYTECH to Host Third Quarter 2017 Conference Call and Business Update on November 14, 2017

  11/13/2017

  ERYTECH announced that it will host a Third Quarter 2017 conference call and webcast on Tuesday, November 14, 2017, at 2:30 PM CET/8:30 AM EST to discuss operational highlights.

• ERYTECH Reports Third Quarter 2017 Financial Results and Provides Business Update

  11/7/2017

  Net loss for the nine-month period ended September 30, 2017 was €20.8 million, compared to €16.1 million for the same period in the prior year.

• ERYtech Pharma Announces Resubmission Of European Marketing Authorization Application For GRASPA In Acute Lymphoblastic Leukemia

  10/10/2017

• France-Based ERYtech Pharma Files for $100 Million IPO

  10/9/2017

• ERYtech Pharma Reports Determination Of The Recommended Pivotal Phase 3 Dose Of Eryaspase In Its U.S. Phase 1 Study In First Line Adult ALL

  9/28/2017

• ERYtech Pharma Reports First Half 2017 Financial Results And Provides Business Update

  9/11/2017

• ERYtech Pharma Announces Positive Full Results From Phase IIb Study Of Eryaspase In Combination With Chemotherapy For Treatment Of Metastatic Pancreatic Cancer In Second-Line

  9/8/2017

• ERYtech PharmaTo Host Second Quarter 2017 Conference Call And Business Update

  9/6/2017

• ERYtech Pharma To Present Pre-Clinical Data At The 13th International Congress Of Inborn Errors Of Metabolism

  9/1/2017

• ERYtech Pharma To Present Full Results For Phase IIb Trial Of Eryaspase In Pancreatic Cancer At ESMO 2017

  8/31/2017

• ERYtech Pharma Announces Collaboration With Queen’s University To Advance Its Product Candidate For Rare Metabolic Disorders

  7/12/2017

• ERYtech Pharma Provides Business Update And Financial Highlights For Q1 2017

  5/19/2017

• ERYtech Pharma Announces Launch Of Investigator-Initiated Phase II Study Of Eryaspase (GRASPA) For ALL

  4/4/2017

• ERYtech Pharma Reports Positive Phase IIb Data For Eryaspase For The Treatment Of Metastatic Pancreatic Cancer

  3/27/2017